Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application

Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application

Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risk of fragility fractures and significant long-term disability. Although both anti-resorptive treatments and osteoanabolic drugs, such as parathyroid hormone analogues, are effective in f...

Full description

Bibliographic Details
Main Authors: Martina Rauner, Hanna Taipaleenmäki, Elena Tsourdi, Elizabeth M. Winter
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Journal of Clinical Medicine
Subjects:
sclerostin
wnt signaling
osteoblast
osteoclast
osteoporosis
romosozumab
Online Access:https://www.mdpi.com/2077-0383/10/4/787

Similar Items

Similar Items